Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer
Sponsor: Qilu Hospital of Shandong University
Summary
This preliminary clinical study evaluates the safety and initial efficacy of a novel therapy called Plasma-Activated Saline Solution (PASS) for bladder cancer patients. The study involves a one-week course of PASS administered via bladder infusion in five pre-surgical patients, using imaging and pathology analyses to assess tumor shrinkage and cancer cell death, while closely monitoring for any adverse reactions to explore the therapy's future potential.
Official title: Preliminary Clinical Study Evaluating the Therapeutic Response and Safety of Intravesical Perfusion With Plasma-Activated Saline Solution in Patients With Bladder Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2025-12-15
Completion Date
2026-02-15
Last Updated
2025-12-09
Healthy Volunteers
No
Interventions
Plasma-Activated Saline Solution (PASS) Bladder Instillation
This intervention is distinguished by its unique mechanism of action, which utilizes physically-activated normal saline infused with reactive oxygen and nitrogen species (RONS) generated by non-thermal plasma, creating a potent yet transient cytotoxic solution that is administered locally.